Vivani to Merge Cortigent with Nasdaq Firm ClearOne in Rebranding Deal
Vivani Medical plans to fold subsidiary Cortigent into ClearOne, renaming the Nasdaq-listed company Cortigent Holdings under ticker 'CRGT'.
Vivani Medical announced plans to merge its wholly owned subsidiary Cortigent, Inc. with a subsidiary of Nasdaq-listed ClearOne, Inc. (CLRO) in a deal that would fundamentally transform the publicly traded communications technology company into a neurotechnology-focused entity.
Under the terms of the proposed merger agreement, ClearOne would be renamed Cortigent Holdings, Inc. — doing business as Cortigent — and would trade on the Nasdaq exchange under the new ticker symbol "CRGT," effectively giving Vivani's subsidiary a public market listing through the transaction.
Read more Intel Falls 6%, AMD Drops 5% as Chip Stocks Sell Off Hard →
The move represents a strategic pivot for ClearOne, which currently operates in the audio and visual communications space. By absorbing Cortigent through the merger structure, the combined company would carry Cortigent's identity and presumably its neurotechnology focus into the public markets, while retaining the established Nasdaq listing that ClearOne currently holds.
The transaction follows a familiar playbook in biotech and medtech, where private or subsidiary-stage companies gain public market access through mergers with existing Nasdaq or NYSE entities rather than pursuing a traditional IPO — a route that can be faster and less capital-intensive in volatile market conditions. Vivani retains strategic leverage in the outcome by engineering the deal through a wholly owned subsidiary structure.
Full terms of the merger agreement, including shareholder votes, regulatory approvals, and closing timelines, were not detailed in the initial announcement. Continue reading at GlobalNewswire.
